INO240927C6000
- 0.20
- 0.000.00%
Inovio Pharmaceuticals Newsroom
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS) and Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals (INO) Receives a Buy From Oppenheimer
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals: Hold Rating Amidst Financial Concerns and INO-3107 Development Delays
RBC Cuts Price Target on Inovio Pharmaceuticals to $8 From $11, Keeps Sector Perform, Speculative Risk
Inovio Pharmaceuticals: Maintaining Buy Rating Amid BLA Submission Delay
Analysts Conflicted on These Healthcare Names: Daiichi Sankyo Company (OtherDSKYF), Inovio Pharmaceuticals (INO) and Molina Healthcare (MOH)
Inovio Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
Inovio Pharmaceuticals Receives 'Buy' Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals: Hold Rating Amidst Clinical Progress and Financial Caution
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals: Hold Rating With Promising Pipeline Despite Financial Losses
RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals Analyst Ratings
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target
JMP Securities Initiates Coverage On Inovio Pharmaceuticals With Market Outperform Rating, Announces Price Target of $1